AI Bias Analysis
4 models · Takes ~15 seconds
(MedPage Today) -- NEW ORLEANS -- Injections of an ultra-long-acting investigational GLP-1 agonist led to significant weight loss in people with overweight or obesity, with reductions continuing after a switch to once-monthly dosing, according...
Source
MedPage Today
Opens original article in a new tab
Health workers at the epicenter of Congo's Ebola outbreak are laboring with little pay or rest.
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
(MedPage Today) -- Patients taking GLP-1 receptor agonists for obesity had a 41% lower risk of obesity-related cancers as compared with patients treated with diet or exercise, a large propensity-matched cohort study showed. After 2 years of follow...
(MedPage Today) -- NEW ORLEANS -- A fixed-dose combination of novel amylin analog cagrilintide and semaglutide, given once weekly, lowered blood glucose and weight in various populations with type 2 diabetes. The combination injectable, dubbed...
